MTAP Antibody (1113601) [Alexa Fluor® 405]

• Reactivity: Hu
• Applications: WB, IHC, ICC/IF
• Clone: 1113601
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 405

MTAP Antibody (1113601) [Alexa Fluor® 405] Summary

• Immunogen: E. coli-derived recombinant human MTAP
  Accession # Q13126
• Specificity: Detects recombinant human MTAP protein in Direct ELISA
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry
  • Immunohistochemistry
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for MTAP Antibody (1113601) [Alexa Fluor® 405]

• 5'-methylthioadenosine phosphorylase
• BDMF
• C86fus
• DMSFH
• DMSMFH
• EC 2.4.2.28
• HEL-249
• LGMBF
• methylthioadenosine phosphorylase
• MSAPMeSAdo phosphorylase
• MTA phosphorylase
• MTAP
• MTAPase
• S-methyl-5'-thioadenosine phosphorylase

Background

Methyl-thioadenosine phosphorylase/MTAP is part of the PNP/MTAP phosphorylase family and catalyzes the reversible phosphorylation of S-methyl-5'-thioadenosine (MTA), a major byproduct of polyamine synthesis essential for cell growth and proliferation. MTAP also produces most of the free adenine generated in human cells through a salvage pathway and thus couples the purine salvage pathway with polyamine biosynthesis. MTAP forms an active trimer where each identical 32 kDa monomer contains a separate active site (1). Each active site contains three distinct regions required for base-, methylthioribose-, and sulfate/phosphate-binding (1). MTAP is cytosolic and abundantly expressed in normal cells and tissues (2). In contrast, deficient MTAP expression is observed in many types of tumors including lung, bladder, pancreatic, and endometrial cancer (3) due to hyper-methylation gene suppression (4) or gene deletion (3, 5, 6). MTA accumulation leads to an immunosuppressive tumor microenvironment and apoptotic resistance (7-9) and MTAP directly regulates the level of MTA present. MTAP has been reported as a tumor suppressor (6,10) that may also act in a manner that is independent of enzymatic activity (11) through signaling pathways such as the insulin-like growth factor-1 receptor pathway (12). Potential therapeutic strategies to exploit MTAP deficiency in tumors (13,14) or inhibit MTAP in tumors that express MTAP, such as prostate cancer, are under investigation (15).

1. Appleby, T.C. et al. (1999) Structure 7:629.
2. Garbers, D.L. (1978) Biochim. Biophys. Acta. 523:82.
3. Li, Y. et al. (2019) J. Cancer 10:927.
4. Hellerbrand, C. et al. (2006) Carcinogenesis 27:64.
5. Cairns, P. et al. (1995) Nat. Genet. 11:210.
6. Christopher, S.A. (2002) Cancer Res. 62:6639.
7. Kirovski, G. et al. (2011) Am. J. Pathol. 178:1145.
8. Czech, B. et al. (2013) PLoS One 8:e80703.
9. Henrich, F.C. et al. (2016) Oncoimmunology 5:e1184802.
10. Kadariya, Y. et al. (2009) Cancer Res. 69:5961.
11. Tang, B. et al. (2014) G3 (Bethesda) 5:35.
12. Xu, J. et al. (2019) Signal Transduct. Target Ther. 4:2.
13. Bertino, J.R. et al. (2011) Cancer Biol. Ther. 11:627.
14. Tang, B. et al. (2018) Cancer Res. 78:4386.
15. Bistulfi, G. et al. (2016) Oncotarget 7:14380.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • Q13126(Human)